Resapp Health Ltd is primarily active in the healthcare industry.

The main competitors of Resapp Health Ltd in the market include companies such as ResMed Inc., Fisher & Paykel Healthcare Corporation Limited, and Masimo Corporation.

Resapp Health Ltd, an innovative healthcare company, has a notable history and background. Founded in 2014, Resapp is dedicated to developing digital healthcare solutions centered around respiratory diseases. The company focuses on creating intelligent software that can diagnose and manage respiratory conditions using cough sounds and patient data. Resapp Health Ltd operates in the global market and has expanded its reach by collaborating with renowned medical institutions and research centers. With its cutting-edge technology and a team of experienced professionals, Resapp Health Ltd strives to improve the healthcare landscape and provide effective solutions for respiratory health.

Resapp Health Ltd has achieved a number of significant milestones. They successfully developed and launched ResAppDx, a smartphone-based diagnostic test for respiratory diseases. The company also received regulatory clearance in both the United States and European Union for their products. Resapp Health Ltd has entered into partnerships with leading healthcare institutions and companies to advance their technology and expand their market reach. They have conducted several successful clinical studies validating the accuracy and effectiveness of their diagnostic platform. Resapp Health Ltd's continuous innovation and commitment to improving respiratory healthcare positions them as a leader in the field.

Resapp Health Ltd is primarily present in Australia and the United States.

Resapp Health Ltd is a leading digital health company that focuses on developing innovative solutions to improve respiratory diagnostics and management. The company's values revolve around delivering accurate, accessible, and cost-effective healthcare solutions. Resapp Health is committed to leveraging cutting-edge technology and research to positively impact patient outcomes and healthcare efficiency. With a customer-centric approach, the company prioritizes collaboration, transparency, and integrity in all its endeavors. By constantly pushing the boundaries of respiratory healthcare, Resapp Health aims to revolutionize the industry and make a meaningful difference in the lives of individuals worldwide.

Analysts currently set an average price target of 0,23 AUD for the Resapp Health stock (median: 0,23 AUD), implying +838,4 % versus the latest price. The consensus is based on 6 analyst ratings.

Resapp Health Analyytikkojen kursstavoitteet 2026

5 analysts currently rate the Resapp Health stock: 4 recommend buying, 1 holding and 0 selling.

Resapp Health Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Resapp Health share trades at 0,02 EUR (0,03 AUD).

ResApp Health Ltd is an Australian company that develops innovative digital health solutions based on artificial intelligence. The company's business model is to optimize healthcare in various areas by offering its proprietary technologies and products. ResApp Health's main areas of focus are the diagnosis and treatment of respiratory diseases, particularly in children. The company has developed a patented technology that analyzes cough sounds to support the diagnosis of conditions such as asthma, bronchitis, or pneumonia. This technology is available in the form of a mobile app that allows parents and caregivers to record cough sounds and receive a diagnosis within minutes. ResApp Health has also developed products and technologies to support healthcare professionals in the diagnosis of respiratory diseases. The company has developed a portable device called "Smarthaler" that monitors patients' airways and captures measurements such as respiratory rate and volume. These data are transmitted in real-time to an app that helps doctors and nurses detect conditions early and respond to changes more quickly. Another division of ResApp Health is telemedicine. The company has developed a platform that allows patients and doctors to communicate from anywhere. This platform offers various telemedicine services such as video consultations, electronic prescriptions, or digital medical records. This allows patients, especially those in rural areas or with limited mobility, to benefit from better healthcare. ResApp Health works closely with medical institutions and research facilities to improve and develop its technologies and products. The company has partnerships with renowned research institutions such as the University of Queensland or the Cleveland Clinic to conduct clinical studies and validate its technologies. The business model of ResApp Health is based on a mixture of products and services that improve healthcare in an innovative and intuitive way. The patented technology for the diagnosis of respiratory diseases enables rapid and accurate diagnosis, while the portable device and telemedicine platform make healthcare more efficient and accessible. ResApp Health has a wide range of application areas such as pediatrics, geriatrics, or general medicine, making it a promising company in the field of digital health.

Liikevaihtoa ei voida laskea Resapp Health:lle tällä hetkellä.

Voittoa ei voida laskea Resapp Health:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Resapp Health:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Resapp Health:lle tällä hetkellä.

Resapp Health:n Eulpool-laatuscore on 4/10.

Resapp Health:n ISIN on AU000000RAP5. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Resapp Health:n ticker on RAP.AX. Tämä pörssinoteeraus käytetään Resapp Health-osakkeiden kauppaan pörssissä.

Resapp Health maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Resapp Health kuuluu sektoriin 'Terveydenhuolto'.

Resapp Health:n osingot jaetaan valuutassa AUD.